

Competing interests None.

Contributors K S Boparai: analysis, author. E Dekker: analysis, coauthor. J H Reitsma: statistical data analysis.

Provenance and peer review Not commissioned; internally peer reviewed.

Published Online First 22 September 2011

Gut 2012;**61**:471–472. doi:10.1136/gutjnl-2011-300680

REFERENCES

1. **Boparai KS**, Reitsma JB, Lemmens V, *et al*. Increased colorectal cancer risk in first-degree relatives of HPS patients. *Gut* 2010;**59**:1222–5.
2. **Boparai KS**, Mathus-Vliegen EM, Koorstra JJ, *et al*. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. *Gut* 2010;**59**:1094–100.
3. **Orlowska J**. Hyperplastic polyposis syndrome and the risk of colorectal cancer. *Gut* 2012;**61**:470–1.
4. **Spring KJ**, Zhao ZZ, Karamatic R, *et al*. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. *Gastroenterology* 2006;**131**:1400–7.
5. **Winawer S**, Fletcher R, Rex D, *et al*: Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. *Gastroenterology* 2003;**124**:544–60.
6. **Edge S**, Byrd D, Compton C. *AJCC (American Joint Committee on Cancer), cancer staging manual*. Springer, New York, USA, 2010:143.
7. **Lockett MJ**, Atkin WS. Hyperplastic polyposis: prevalence and cancer risk. *Gut* 2001;**48**:A4.
8. **Orlowska J**, Kiedrowski M, Kaminski FM, *et al*. Hyperplastic polyposis syndrome in asymptomatic patients: the results from the colorectal-cancer screening program. *Virchows Arch* 2009;**455**:S–47.
9. **Lage P**, Cravo M, Sousa R, *et al*. Management of Portuguese patients with hyperplastic polyposis and screening of at-risk first-degree relatives: a contribution for future guidelines based on a clinical study. *Am J Gastroenterol* 2004;**99**:1779–84.

The need for standardised outcome reporting in colorectal surgery

We were interested to read the paper by Morris *et al* demonstrating significant variation in 30-day postoperative mortality following major colorectal cancer surgery in National Health Service hospitals in England.¹ While we agree that understanding the underlying causes of this vari-

ation will be invaluable to inform best practice, we think that it is necessary to choose a definition of postoperative mortality that provides information relevant to patients as well as clinicians. In cardiothoracic surgery, this issue has been debated for some years, resulting in a measure of ‘operative mortality’ which encompasses any death occurring (a) within 30 days after surgery, in or out of hospital, and (b) any death occurring after 30 days during the same hospitalisation subsequent to the operation.² Implementing the use of this expanded definition is more complex, but it will provide data about the real risks of surgery where a prolonged stay in an intensive care unit may mean that a postoperative death occurs beyond 30 days. From the patient’s perspective, understanding outcomes of surgery including the chances of dying within the same hospital stay or shortly after discharge (but within 30 days) is what matters. This issue of defining surgical outcomes extends beyond mortality reporting. Events such as an anastomotic leak are important to measure, but numerous definitions exist for this term.³ The lack of uniformity of outcome reporting means that it can be difficult to compare centres and to summarise data in systematic reviews and meta-analyses. One solution to this problem is to create ‘core outcomes sets’, which include end points to be reported as a minimum in all studies of a particular condition. The use of core outcome sets in clinical audit, prospective studies and randomised controlled trials would reduce some of these problems. The Core Outcome Measurement in Effectiveness Trials initiative facilitates development of such measures in all areas of health care, with the aim of improving data synthesis and reducing outcome reporting bias.⁴ We are developing a core outcome set for colorectal cancer surgery—whether 30-day postoperative mortality or operative mortality (including all postoperative deaths) will be part of the core outcome set is yet to be decided.

**R N Whistance,^{1,2} N S Blencowe,^{1,2}
J M Blazeby^{1,2}**

¹Division of Surgery, Head and Neck, University Hospitals Bristol NHS Foundation Trust, Bristol, UK; ²Surgical

Research Unit, School of Social and Community Medicine, University of Bristol, Bristol, UK

Correspondence to Robert Whistance, School of Social and Community Medicine, University of Bristol, Bristol, UK; robert.whistance@hotmail.co.uk

Funding RNW holds a National Institute for Health Research Doctoral Research Fellowship award. JMB is funded in part by the UK Medical Research Council.

Competing interests None declared.

Contributors All authors participated in the 1) conception and design, or analysis and interpretation of data, 2) drafting the article or revising it critically for important intellectual content and 3) final approval of the version to be published.

Provenance and peer review Not commissioned; internally peer reviewed.

Published Online First 8 July 2011

Gut 2012;**61**:472. doi:10.1136/gutjnl-2011-300676

REFERENCES

1. **Morris EJ**, Taylor EF, Thomas JD, *et al*. Thirty-day postoperative mortality after colorectal cancer surgery in England. *Gut* 2011;**60**:806–13.
2. **Jacobs JP**, Mavroudis C, Jacobs ML, *et al*. What is operative mortality? Defining death in a surgical registry database: a report of the STS congenital database taskforce and the joint EACTSSTS congenital database committee. *Ann Thorac Surg* 2006;**81**:1937–41.
3. **Bruce J**, Krukowski ZH, Al-Khairy G, *et al*. Systematic review of the definition and measurement of anastomotic leak after gastrointestinal surgery. *Br J Surg* 2001;**88**:1157–68.
4. **COMET initiative**. http://www.liv.ac.uk/nwhtmr/comet/core_outcomes.htm (accessed 18 Jun 2011).

CORRECTION

doi:10.1136/gutjnl-2011-300113corr1

Benamouzig R, Uzzan B, Deyra J, *et al*. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. *Gut* 2012;**61**:255–61.

There are two numerical errors in the last sentence of the “Results” paragraph of the Abstract of this paper. This sentence should be read as follows: “Also, the proportion of patients with at least one advanced adenoma did not differ (10/102 (10%) in the aspirin group vs 7/83 (8.4%) in the placebo group; NS).”



The need for standardised outcome reporting in colorectal surgery

R N Whistance, N S Blencowe and J M Blazeby

Gut 2012 61: 472 originally published online July 8, 2011
doi: 10.1136/gutjnl-2011-300676

Updated information and services can be found at:
<http://gut.bmj.com/content/61/3/472.1>

These include:

References

This article cites 3 articles, 1 of which you can access for free at:
<http://gut.bmj.com/content/61/3/472.1#ref-list-1>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>